Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
- The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
- General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
- The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
- Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.